Page last updated: 2024-12-11
corynomycolic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
corynomycolic acid: linked as 6,6'-dicorynomycolyl-trehalose (cord factor structure) in Brevibacterium vitarumen [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
corynomycolic acid : A thirty-two membered mycolic acid consisting of 3-hydroxystearic acid having a tetradecyl group at the 2-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 12304080 |
CHEBI ID | 60916 |
SCHEMBL ID | 161181 |
MeSH ID | M0062029 |
Synonyms (9)
Synonym |
---|
3-hydroxy-2-tetradecyloctadecanoic acid |
CHEBI:60916 |
mycolic acid (c32) |
synthetic mycolic acid |
corynomycolic acid |
SCHEMBL161181 |
2-n-tetradecyl-3-hydroxy-stearic acid |
LMFA01050506 |
Q27129803 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
Class | Description |
---|---|
mycolic acid | Mycolic acids are alpha-branched, beta-hydroxy long-chain fatty acids found in the cell walls of the mycolata taxon, a group of bacteria that includes Mycobacterium tuberculosis, the causative agent of the disease tuberculosis. |
3-hydroxy fatty acid | Any fatty acid with a hydroxy functional group in the beta- or 3-position. beta-Hydroxy fatty acids accumulate during cardiac hypoxia, and can also be used as chemical markers of bacterial endotoxins. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (20)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (15.00) | 18.7374 |
1990's | 4 (20.00) | 18.2507 |
2000's | 7 (35.00) | 29.6817 |
2010's | 5 (25.00) | 24.3611 |
2020's | 1 (5.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (5.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 19 (95.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |